Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 9/20 | 0.41 |
| ▸ | CCND1 | P24385 | 9/20 | 0.41 |
| ▸ | CCNE2 | O96020 | 7/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.41 |
| ▸ | CDK2 | P24941 | 7/20 | 0.41 |
| ▸ | CAMK2D | Q13557 | 6/20 | 0.41 |
| ▸ | PRKCB | P05771 | 6/20 | 0.41 |
| ▸ | PRKCA | P17252 | 6/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 5/20 | 0.41 |
| ▸ | CDK1 | P06493 | 5/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 5/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 5/20 | 0.41 |
| ▸ | PRKCG | P05129 | 5/20 | 0.41 |
| ▸ | PRKCH | P24723 | 5/20 | 0.41 |
| ▸ | PRKCI | P41743 | 5/20 | 0.41 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.41 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6860525 | 0.96 | CDK4 (0.40) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL6867375 | 0.96 | CDK4 (0.40) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL6867156 | 0.96 | CDK4 (0.40) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL7873230 | 0.84 | CDK4 (0.42) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL19217026 | 0.80 | CAMK2D (0.50) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL7785201 | 0.78 | CAMK2D (0.61) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL5686010 | 0.78 | CAMK2D (0.50) | CAMK2DPRKCBPRKCAPRKCHPRKCE | |
| SCHEMBL6991740 | 0.77 | GSK3B (0.44) | CDK4CCND1CAMK2DPRKACAPRKACG | |
| SCHEMBL6860161 | 0.76 | CDK4 (0.40) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL5683201 | 0.76 | CAMK2D (0.50) | CDK4CCND1CCNE2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812243-B2 | AS TYROSINE KINASE INHIBITORS; FOR THERARPY OF TUMORS, ARTERIOSCLEROSIS, RESTENOSIS AFTER BALLOON ANGIOPLASTY, ARTHRITIS AND FIBROTIC DISEASES | ZENTARIS AG (DE) | 2004-11-02 | — | — | US | disclosed |
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | ZENTARIS AG (DE) | 2003-01-09 | — | — | US | disclosed |
| EP-1109785-B1 | INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MALIGNANT AND OTHER DISEASES CAUSED BY PATHOLOGICAL CELL PROLIFERATION | ZENTARIS AG (DE) | 2003-01-02 | — | — | EP | disclosed |
| US-6407102-B1 | TYROSINE KINASE AND PLATELET-DERIVED GROWTH FACTOR INHIBITORS; ANTICARCINOGENIC, ANTITUMOR, ANTIARTHRITIC AND ANTIPROLIFERATIVE AGENTS; RESTENOSIS, ARTERIOSCLEROSIS | ZENTARIS AG (DE) | 2002-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | MKI67, IDO1, CCNI | CDK4 22/4885CCND1 52/4885CCNE2 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.